SCHEMBL826985

SCHEMBL826985

CCOc1cc2cc(C)ccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.47
CYP1A2 P05177 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 3/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
AKR1B1 P15121 1/20 0.35
PTPN1 P18031 1/20 0.35
KDM4E B2RXH2 4/20 0.34
MAPT P10636 3/20 0.34
RAB9A P51151 2/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
POLB P06746 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL826722 0.79 CYP2A6 (0.52) CYP2A6CYP1A2ALDH1A1TP53CYP3A4
SCHEMBL9198335 0.77 CYP2A6 (0.47) CYP2A6CYP1A2TRPM8ALDH1A1HSD17B10
SCHEMBL6958993 0.73 CYP2A6 (0.50) CYP2A6CYP1A2TRPM8AKR1B1KDM4E
SCHEMBL2943665 0.73 CYP2A6 (0.46) CYP2A6CYP1A2TRPM8KMT2AAKR1B1
SCHEMBL12269167 0.73 ALDH1A1 (0.35) CYP1A2ALDH1A1HSD17B10TP53CYP3A4
SCHEMBL13201401 0.73 CYP2A6 (0.42) CYP2A6CYP1A2TRPM8ALDH1A1HSD17B10
SCHEMBL5233617 0.71 CYP2A6 (0.53) CYP2A6TRPM8KMT2AAKR1B1MAPT
SCHEMBL1205380 0.71 PTPN2 (0.51) CYP2A6TRPM8ALDH1A1HSD17B10KMT2A
SCHEMBL12430648 0.71 CYP2A6 (0.57) CYP2A6CYP1A2TRPM8TP53AKR1B1
SCHEMBL144441 0.71 CYP2A6 (0.57) CYP2A6CYP1A2TRPM8ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507680-B2 Production process of a heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2013-08-13 US disclosed
US-20120142924-A1 PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO., LTD. (JP) 2012-06-07 US disclosed
US-8143407-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2012-03-27 US disclosed
EP-1481978-B1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO (JP) 2011-09-14 EP disclosed
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO., LTD. (JP) 2010-01-14 US disclosed
US-7612218-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2009-11-03 US disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST PIN4, IPO5, HLCS CYP2A6 405/4885CYP1A2 885/4885TRPM8 2250/4885
US-20120142924-A1 PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST PIN4, NISCH, HLCS CYP2A6 560/4885CYP1A2 943/4885TRPM8 2784/4885
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS CYP2A6 405/4885CYP1A2 885/4885TRPM8 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.